ARWR · Insider Trading
Arrowhead Research Corporation
Every open-market purchase and sale reported by ARWR officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-20 | Michael S Perry | Director | Sell | −11,600 | −$1.01M |
| 2026-08-20 | Adeoye Y Olukotun | Director | Sell | −2,000 | −$173.92K |
| 2026-06-17 | Matthew Gregory Cohen | Director | A | +11,882 | — |
| 2026-05-14 | Hongbo Lu | Director | Sell | −2,970 | −$228.33K |
| 2026-04-24 | James C Hamilton | Chief Medical Officer | Sell | −10,000 | −$750.00K |
| 2026-04-24 | Daniel Joseph Apel | Chief Financial Officer | Sell | −13,095 | −$934.29K |
| 2026-03-09 | James C Hamilton | Chief Medical Officer | Sell | −10,000 | −$641.90K |
| 2026-01-08 | Patrick O'Brien | COO | MIXED | +72,500 | — |
| 2026-01-08 | Daniel Joseph Apel | Chief Financial Officer | A | +75,000 | — |
| 2026-01-08 | James C Hamilton | Chief Medical Officer | A | +75,000 | — |
| 2026-01-05 | Christopher Richard Anzalone | Chief Executive Officer | Sell | −13,187 | −$871.70K |
| 2026-01-05 | James C Hamilton | Chief Medical Officer | Sell | −40,164 | −$2.53M |
| 2026-01-05 | Patrick O'Brien | COO | MIXED | −52,293 | −$3.12M |
| 2025-12-30 | Mauro Ferrari | Director | Sell | −7,530 | −$527.10K |
| 2025-12-30 | Christopher Richard Anzalone | Chief Executive Officer | MIXED | — | −$3.26M |
| 2025-12-23 | Adeoye Y Olukotun | Director | Sell | −10,000 | −$676.62K |
| 2025-12-23 | Christopher Richard Anzalone | Chief Executive Officer | Sell | −26,031 | −$1.77M |
| 2025-12-23 | Victoria Vakiener | Director | Sell | −10,040 | −$679.49K |
| 2025-12-23 | William D. Waddill | Director | Sell | −8,367 | −$566.04K |
| 2025-12-19 | Christopher Richard Anzalone | Chief Executive Officer | Sell | −85,000 | −$5.44M |
| 2025-12-18 | William D. Waddill | Director | A | +7,819 | — |
| 2025-12-18 | Adeoye Y Olukotun | Director | A | +7,819 | — |
| 2025-12-18 | Douglas S Ingram | Director | A | +7,819 | — |
| 2025-12-18 | Victoria Vakiener | Director | A | +7,819 | — |
| 2025-12-18 | Michael S Perry | Director | A | +7,819 | — |
| 2025-12-18 | Hongbo Lu | Director | A | +7,819 | — |
| 2025-12-18 | Mauro Ferrari | Director | A | +7,819 | — |
| 2025-12-16 | Christopher Richard Anzalone | Chief Executive Officer | MIXED | −4,298 | −$12.35M |
| 2025-12-09 | Michael S Perry | Director | Sell | −16,250 | −$991.74K |
| 2025-12-01 | Mauro Ferrari | Director | Sell | −8,750 | −$493.41K |
| 2025-10-03 | James C Hamilton | Chief Medical Officer | Sell | −20,000 | −$700.00K |
| 2025-09-16 | James C Hamilton | Chief Medical Officer | Sell | −15,000 | −$450.00K |
| 2025-09-04 | James C Hamilton | Chief Medical Officer | Sell | −15,000 | −$375.00K |
| 2025-08-15 | James C Hamilton | Chief Medical Officer | Sell | −10,000 | −$200.00K |
| 2025-04-11 | Christopher Richard Anzalone | Chief Executive Officer | Sell | −141,122 | −$1.53M |
| 2025-03-17 | Christopher Richard Anzalone | Chief Executive Officer | MIXED | +288,575 | −$774.97K |
| 2025-03-05 | Christopher Richard Anzalone | Chief Executive Officer | MIXED | — | −$2.95M |
| 2025-02-10 | Christopher Richard Anzalone | Chief Executive Officer | A | +9,550 | +$191.96K |
| 2025-02-07 | Douglas S Ingram | Director | A | +38,396 | +$771.38K |
| 2025-01-27 | Adeoye Y Olukotun | Director | Sell | −959 | −$20.14K |
| 2025-01-07 | Kenneth Allen Myszkowski | Chief Financial Officer | MIXED | +54,833 | −$893.10K |
| 2025-01-07 | Patrick O'Brien | COO and General Counsel | MIXED | +62,816 | −$736.06K |
| 2025-01-07 | James C Hamilton | Chief Discovery/Trans Medicine | MIXED | +67,271 | −$648.82K |
| 2025-01-06 | Christopher Richard Anzalone | Chief Executive Officer | Sell | −11,520 | −$219.46K |
| 2024-12-30 | Adeoye Y Olukotun | Director | Sell | −2,850 | −$57.00K |
| 2024-12-23 | Christopher Richard Anzalone | Chief Executive Officer | Sell | −12,563 | −$246.11K |
| 2024-12-20 | Christopher Richard Anzalone | Chief Executive Officer | MIXED | +73,288 | −$567.49K |
| 2024-12-20 | Hongbo Lu | Director | A | +16,733 | +$384.69K |
| 2024-12-20 | Michael S Perry | Director | A | +16,733 | +$384.69K |
| 2024-12-20 | Mauro Ferrari | Director | A | +16,733 | +$384.69K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Christopher Richard Anzalone | Chief Executive Officer | 3,792,739 | $220.59M |
| Kenneth Allen Myszkowski | Chief Financial Officer | 473,433 | $27.53M |
| Patrick O'Brien | COO | 472,848 | $27.50M |
| James C Hamilton | Chief Medical Officer | 226,958 | $13.20M |
| Daniel Joseph Apel | Chief Financial Officer | 162,905 | $9.47M |
| Douglas B Given | Director | 137,214 | $7.98M |
| Michael S Perry | Director | 111,459 | $6.48M |
| Mauro Ferrari | Director | 69,053 | $4.02M |
| William D. Waddill | Director | 56,563 | $3.29M |
| Hongbo Lu | Director | 52,012 | $3.03M |
| Douglas S Ingram | Director | 46,215 | $2.69M |
| Victoria Vakiener | Director | 42,964 | $2.50M |
| Adeoye Y Olukotun | Director | 31,600 | $1.84M |
| Matthew Gregory Cohen | Director | 11,882 | $691.06K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ARWR quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.